Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer-Reference-Cited by-同舟云学术

Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer

Published:2014-09 Issue:3 Volume:13 Page:164-171
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Morris Van,Overman Michael J.,Jiang Zhi-Qin,Garrett Christopher,Agarwal Shweta,Eng Cathy,Kee Bryan,Fogelman David,Dasari Arvind,Wolff Robert,Maru Dipen,Kopetz Scott

Funder

National Institute of Health

Cancer Center Support

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference35 articles.

1. Cancer treatment and survivorship statistics, 2012;Siegel;CA Cancer J Clin,2012

2. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial;Nordlinger;Lancet,2008

3. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR;Andre;Eur J Cancer,1999

4. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study;Fuchs;J Clin Oncol,2007

5. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer;Kabbinavar;J Clin Oncol,2003

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BRAF-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities;Clinical Colorectal Cancer;2024-09

2. A comprehensive overview of the molecular features and therapeutic targets in BRAF^V600E‐mutant colorectal cancer;Clinical and Translational Medicine;2024-07

3. Utility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer;Journal of the American College of Surgeons;2024-02-01

4. Small-molecule drugs of colorectal cancer: Current status and future directions;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-01

5. Biomarkers in Cancer Detection, Diagnosis, and Prognosis;Sensors;2023-12-20